BioCatalystWatch
HOWLWorkspace / HOWL / OverviewCompany library
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. (HOWL)

Website

Featured programme · WTX-1011

Price
Market cap
Next catalyst—
Cash

Chart & Events

Candle interval

Core Clinical

WTX-1011

T-cell engager

STEAP1 × CD3

WTX-2022

T-cell engager

CDH6 × CD3

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

WTX-1011

T-cell engager

STEAP1 × CD3

WTX-2022

T-cell engager

CDH6 × CD3

Other pipelines

WTX-712

WTX-518

WTX-921

IL-10 INDUKINE molecules

PreINDP1P2P3FilingApproved

Partner / License out

IFNα receptors

PreINDP1P2P3FilingApproved

History / paused

IL-2R

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

HOWL PR & News

PR & News

HOWL SEC archive